Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2022-10-19
DOI
10.1016/j.ejca.2022.10.003
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Does Knowledge of Treatment Assignment Affect Patient Report Of Symptoms, Function, and Health Status? An Evaluation Using Multiple Myeloma Trials
- (2021) Jessica K. Roydhouse et al. VALUE IN HEALTH
- Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities
- (2021) Laura M. Spring et al. ONCOLOGIST
- Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer
- (2020) S. Adams et al. ANNALS OF ONCOLOGY
- Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
- (2020) Yvonne Brandberg et al. BREAST CANCER RESEARCH AND TREATMENT
- How is the minimal clinically important difference established in health-related quality of life instruments? Review of anchors and methods
- (2020) Yosra Mouelhi et al. Health and Quality of Life Outcomes
- Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015)
- (2018) Fatima Cardoso et al. BREAST
- The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
- (2018) David M. Goldenberg et al. Oncotarget
- General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
- (2018) S. Nolte et al. EUROPEAN JOURNAL OF CANCER
- Long-Term and Latent Side Effects of Specific Cancer Types
- (2017) Nana Gegechkori et al. MEDICAL CLINICS OF NORTH AMERICA
- Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust
- (2016) Johannes M. Giesinger et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Empirical Evidence of Study Design Biases in Randomized Trials: Systematic Review of Meta-Epidemiological Studies
- (2016) Matthew J. Page et al. PLoS One
- Quality of life and metastatic breast cancer: the role of body image, disease site, and time since diagnosis
- (2015) Sara I. McClelland et al. QUALITY OF LIFE RESEARCH
- Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2012) K. Cocks et al. EUROPEAN JOURNAL OF CANCER
- Determining the non-inferiority margin for patient reported outcomes
- (2011) Christoph Gerlinger et al. PHARMACEUTICAL STATISTICS
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2010) Kim Cocks et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now